Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2439-2445

  Ahmed, Fareeda Y ^a   Johnston, Stephen J ^a   Cassidy, James ^a   O'Kelly, Terry ^a   Binnie, Norman ^a   Murray, Graeme I ^a   van Gennip, Albert H ^a   Abeling, Nico G G M ^a   Knight, Sidonie ^a   McLeod, Howard L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; PYRIMIDINE; URACIL;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; PRIORITY JOURNAL;

EID: 0032784111     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2439     Document Type: Article

References (26)

1. Scrip's: Scrip World Pharmaceutical News: Scrip's Cancer Chemotherapy Report. 1996
2. McLeod HL: Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 74:39-54, 1997
3. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
4. Schmoll HJ: Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents. Eur J Cancer 32:S18-S22, 1996(suppl 5)
5. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206, 1987
6. DeMario MD, Ratain MJ: Oral chemotherapy: Rationale and future directions. J Clin Oncol 16:2557-2567, 1998
7. Nightingale CE, Norman A, Cunningham D, et al: A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 33:398-403, 1997
8. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
9. McLeod HL, Sludden J, Murray GI, et al: Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 77:461-465, 1998
10. Jiang WQ, Lu ZH, He YJ, et al: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395-399, 1997
11. Baccanari DP, Davis DT, Knick VC, et al: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-FU. Proc Natl Acad Sci USA 90:11064-11068, 1993
12. Spector T, Cao S, Rustum YM, et al: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55:1239-1241, 1995
13. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994
14. Porter DJT, Chestnut WG, Merrill BM, et al: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethylyluracil. J Biol Chem 267:5236-5242, 1992
15. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996
16. Schilsky RL, Hohneker J, Ratain MJ, et al: Phase I clinical and pharmacological study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450-1457, 1998
17. Spector T, Harrington JA, Parker DJ: 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993
18. McLeod HL, Keith WN: Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74:508-512, 1996
19. van Gennip AH, Busch S, Elzinga L, et al: Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation. Clin Chem 39:380-385, 1993
20. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome. Cancer 68:499-501, 1991
21. Wei X, McLeod HL, McMurrough J, et al: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610-615, 1996
22. Milano G, Etienne MC, Renee N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994
23. Beck A, Etienne MC, Cheradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30:1517-1522, 1994
24. Peters GJ, van Groeningen CJ, Laurensse EJ, et al: A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68:1903-1909, 1991
25. Maehara Y, Moriguchi S, Emi Y, et al: Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas. Cancer 66:156-161, 1990
26. Mani S, Beck T, Chevlen E, et al: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:281a, 1998 (abstr 1083)